Your email has been successfully added to our mailing list.

×
0 0.0126506024096384 0.0126506024096384 0.00602409638554204 0 0 -0.0132530120481929 -0.0518072289156627
Stock impact report

Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity

Kiniksa Pharmaceuticals, Ltd. - Class A (KNSA) 
Last kiniksa pharmaceuticals, ltd. - class a earnings: 8/12 04:02 pm Check Earnings Report
Company Research Source: GlobeNewswire
- ARCALYST® (rilonacept) launched as the first and only FDA-approved therapy for recurrent pericarditis -- Mavrilimumab Phase 2 severe COVID-19 data demonstrated a reduction in mechanical ventilation and death at Day 29; Phase 3 enrollment ongoing -- Final KPL-404 Phase 1 data support further development in patients; Phase 2 proof-of-concept trial initiation planned for 2H 2021 -- Cash reserves of approximately $264 million - HAMILTON, Bermuda, May 04, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today reported first quarter 2021 financial results and recent corporate and portfolio activity. “The first quarter was transformational for Kiniksa with the approval of ARCALYST as the first and only FDA-approved therapy for patients with recurrent pericarditis. We are focused on the launch of ARCALYST and are confident in Show less Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for KNSA alerts
Opt-in for
KNSA alerts

from News Quantified
Opt-in for
KNSA alerts

from News Quantified